ALX Oncology (ALXO) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ALX Oncology (ALXO) has outperformed Veraxa Biotech (VRXA) over the past year, losing 38.3% versus a loss of 88.5%. Veraxa Biotech is the larger company by market cap ($161.2 million vs $159.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | VRXA |
|---|---|---|
| Share price | $1.16 | $1.14 |
| Market cap | $159.71M | $161.20M |
| 1-day change | +2.21% | -4.92% |
| YTD return | 0.00% | -88.75% |
| 1-year return | -38.25% | -88.53% |
| 5-year return | -98.08% | — |
| EPS (TTM) | $-1.13 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $27.36 |
| 52-week low | $1.05 | $1.04 |
| Distance from 52-week high | -56.58% | -95.83% |
| Analyst consensus | none | — |
| Avg. price target upside | +298.27% | — |
| Average volume | 1.02M | 274.75K |
| Shares outstanding | 138.28M | 141.41M |
| Employees | 48 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALXO has outperformed VRXA by 50.3 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
ALXO vs VRXA FAQ
Which is bigger, ALX Oncology or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $161.20M compared with $159.71M for ALX Oncology (ALXO).
Which stock has performed better over the past year, ALXO or VRXA?
ALXO returned -38.25% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.